What Masdil Retard Treats: Main Uses and Benefits

Masdil Retard is commonly used in the management of conditions characterized by periods of heightened symptoms related to cardiovascular stress. The medication is primarily applied in contexts where supportive symptom management is appropriate for moderate arterial hypertension and the management of symptoms associated with angina pectoris, which includes chronic stable angina and angina due to coronary artery spasm (Prinzmetal's angina).

It is used for managing symptom clusters that create noticeable physiological strain, generally contributing to easing the overall symptom load that interferes with daily functioning. This approach helps patients cope more steadily with symptom fluctuations.

“The prolonged-release format is relevant when sustained support for functional stability is needed, such as in long-term chronic management.”

---

Quick Fact: Relief for Angina Pectoris Masdil Retard may assist with easing the frequency and intensity of anginal episodes, which are symptoms related to physical discomfort and organ-specific functional stress.

In addition to its antianginal and antihypertensive uses, the active ingredient is considered relevant for managing certain supraventricular rhythm disorders, specifically assisting with maintaining functional stability in situations involving heightened physiological activity.

Regulatory References

1. Spanish Agency of Medicines and Medical Products (AEMPS) Technical Data Sheet

Who Can and Cannot Use Masdil Retard?

Masdil Retard (diltiazem) is intended for use in adults but is strictly contraindicated in several patient groups due to the risk of serious cardiac complications.

Formal Contraindications (Must Not Use):

• Individuals with known hypersensitivity to diltiazem or any of its components.
• Patients with specific severe heart rhythm disorders, including sick sinus syndrome and second- or third-degree atrioventricular (AV) block, unless a functioning ventricular pacemaker is in place.
• Patients experiencing severe bradycardia (very slow heart rate, e.g., less than 50 beats/minute).
• Patients with cardiogenic shock, acute myocardial infarction with pulmonary congestion, or established left ventricular failure with signs of pulmonary congestion.
• Concomitant use is prohibited with certain medications, including Dantrolene (infusion), Ivabradine, and Lomitapide.

Restrictions and Special Considerations:

• Use in the pediatric population is not established for safety and efficacy and is therefore not recommended.
• Caution and special dosage consideration are necessary for patients with hepatic (liver) impairment or renal (kidney) impairment due to altered drug metabolism and elimination.
• The drug must be used with caution and close monitoring when combined with other agents that affect heart rate or conduction, such as beta-blockers or other antiarrhythmic drugs. Pregnant and lactating individuals should only use this drug if the potential benefit justifies the risk, as documented in official labeling.

Masdil Retard Interactions with Other Medicines and Products

The official interaction profile for Masdil Retard (diltiazem extended-release) identifies specific medicinal products and substances that can significantly affect how the medicine works or is handled by the body.

Impact on Other Medicines

Masdil Retard can increase the levels of certain other medicines in the body, potentially leading to increased effects of the co-administered drug. This category includes:

• Certain cholesterol-lowering medicines (Statins): Examples include atorvastatin and simvastatin.
• Immunosuppressants: Including cyclosporin, sirolimus, and tacrolimus.
• Certain oral anticoagulants and anti-epileptics: For instance, carbamazepine and phenytoin.

Interactions Affecting Cardiac Function

When taken with medicines that also affect heart rate, rhythm, or conduction, Masdil Retard can produce additive effects. These combinations require careful consideration, and include:

• Beta-blockers and other antiarrhythmic medicines: Used to manage heart rhythm.

Contraindicated and Restricted Combinations

Use of Masdil Retard is officially restricted with certain products, including a mandate to avoid taking the medicine with intravenous dantrolene and with ivabradine. Furthermore, specific substances should be avoided, such as grapefruit juice and alcoholic beverages, as they can alter the drug’s concentration in the body.

Administrative Constraints

Some medicines used for stomach acidity, such as cimetidine, are known to increase the concentration of Masdil Retard when taken together, which may require monitoring.

How Masdil Retard Works

Masdil Retard's active ingredient, Diltiazem, exerts a comprehensive cardiovascular mechanism rooted in the selective blockade of L-type Voltage-Gated Calcium Channels ( Ca V1.2). By acting as a non-competitive blocker, the drug restricts the influx of extracellular calcium ions ( Ca^2+) into myocardial cells and arterial smooth muscle cells. This inhibition is rate-dependent (frequency-dependence), intensifying when electrical activity is rapid.

This molecular action creates a dual physiological effect. In the heart's electrical system, it slows the firing rate of the Sinoatrial (SA) node (negative chronotropy) and delays impulse transmission through the Atrioventricular (AV) node (negative dromotropy). Concurrently, reduced Ca^2+ availability in peripheral arteries leads to vasodilation, which lowers the Systemic Vascular Resistance (SVR). The combination of decreased heart rate, reduced contractile force (negative inotropy), and lowered vascular resistance culminates in a decreased myocardial oxygen demand and a rebalancing of the oxygen supply-demand relationship.

The official administration of Masdil Retard is strictly defined by its oral, prolonged-release formulation, which establishes a structured, long-term chronic use pattern. The medicine is taken once daily at approximately the same time each day, as this frequency is essential for maintaining a consistent therapeutic level over 24 hours.

Administration Details (Adults)

Feature	Official Instruction
Route of Administration	Oral (by mouth) only for the prolonged-release tablet.
Dosing Schedule	Initial dose for hypertension or angina is typically 180 mg to 240 mg once daily. The dose is adjusted according to patient response up to a maximum of 540 mg daily for hypertension.
Preparation Requirements	The prolonged-release tablet must be swallowed whole with water and not chewed or crushed. This is a procedural constraint necessary to preserve the controlled release of the medicine.
Timing Constraint	The dose may be administered with or without food, but consistent administration at the same time each day is required.

Dosage adjustments, or titration, occur in intervals of 7 to 14 days, which allows the full pharmacological effect of the steady-state concentration to be established before making changes.

Population and Missed-Dose Instructions

For older adults or patients with impaired hepatic or renal function, it is noted that careful monitoring and the use of a lower initial dose may be necessary. If a once-daily dose is missed, it should be taken as soon as remembered, unless it is less than 12 hours until the next scheduled dose, in which case the missed dose should be skipped.

Research evidence / Overview of Studies for Masdil Retard

Evidence for use in Arterial Hypertension Studies

The research for high blood pressure was observed in different types of clinical investigations, including short-term and longer-term randomized controlled trials (RCTs). Researchers monitored physiological strain by examining outcomes related to systemic or functional imbalance, such as changes in systolic and diastolic blood pressure (SBP/DBP) over 24-hour periods. Findings describe group patterns related to how blood pressure was monitored against target levels during the study periods. Some studies were also observed in observational settings and included tracking long-term outcomes for the drug class. For the specific prolonged-release formulation, long-term effects on complex cardiovascular outcomes are not fully established.

Evidence for use in Angina Pectoris Management

Studies for angina were conducted during trials examining patient-reported experiences relevant in evidence describing how symptoms are measured. Research was observed during periods of increased symptom activity, and studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning, such as exercise tolerance. The findings describe patterns observed in the studies where patients reported outcomes related to physical discomfort, specifically applied in studies examining patient-reported experiences relevant in evidence describing how symptoms are measured. Follow-up durations were limited, with most research exploring short-term symptom changes.

Evidence for use in Heart Rate Control

This medicine was studied for use in conditions associated with acute or disruptive episodes, such as certain supraventricular rhythm disorders. Studies monitored outcomes related to physiological strain, specifically tracking heart rate in populations with functional imbalance. Research describes the study of outcomes related to systemic or functional imbalance. However, comparative evidence is lacking, and there is limited information for long-term outcomes in complex conditions.

---

What Remains Uncertain About the Research Landscape

Evidence is limited for long-term effects on major outcomes because follow-up durations were limited in the most focused studies. There is limited information for long-term outcomes overall. Findings describe group patterns, not personal outcomes. Comparative evidence is lacking in some contexts, and evidence quality varies across studies. The research describes what has been observed and highlights what is known, while acknowledging where evidence is still limited or heterogeneous.

Key Studies & References FICHA TECNICA MASDIL RETARD 120 mg COMPRIMIDOS DE LIBERACION PROLONGADA (Spanish regulator document)

Common questions about Masdil Retard (FAQ)

---

Q: How quickly does Masdil Retard start working?

A: As an extended-release medicine, Masdil Retard is formulated for long-term, stable use over 24 hours. While initial physiological effects may be noticed early, regulatory information indicates that achieving the full, stable therapeutic concentration may take several days to a week.

---

Q: How long does the effect of Masdil Retard last?

A: The 'Retard' designation means this is an extended-release formulation. The prolonged-release formulation is designed to release the active ingredient gradually and continuously, ensuring a consistent therapeutic concentration is maintained in the bloodstream for approximately 24 hours.

---

Q: What should I do if I miss a dose of Masdil Retard?

A: Official instructions state that a missed once-daily dose may be taken as soon as it is remembered. However, if it is less than 12 hours until the next scheduled dose, regulatory guidance advises that the missed dose should be skipped. Regulatory guidelines advise against taking two doses at once to compensate for a missed dose.

---

Q: Are there any known withdrawal symptoms from Masdil Retard?

A: Official warnings indicate that treatment with the active ingredient should not be stopped abruptly, but rather tapered off gradually. This gradual approach is especially important for patients with angina pectoris, as abrupt cessation may be associated with risk.

---

Q: Is it normal to feel dizzy when starting Masdil Retard?

A: Dizziness is an officially listed adverse reaction for this medicine. Regulatory documents classify it as a common effect, meaning it may affect up to 1 in 10 people. This side effect is often reported when a person first starts taking the medication.

---

Q: Does Masdil Retard have an effect on heart rate?

A: Yes, Masdil Retard is known to slow down the heart rate. Its mechanism of action restricts electrical signals in the heart's conduction system, which decreases the heart's pace. This effect is a key part of how the medication works to manage cardiovascular conditions.

---

Q: Is it okay to crush or chew the Masdil Retard tablets?

A: No, the prolonged-release tablet must not be crushed, chewed, or divided. Official directions require the tablet to be swallowed whole with water. This is a critical instruction to ensure the controlled-release system works properly and the medicine is delivered consistently over 24 hours.

---

Q: Can Masdil Retard be taken during pregnancy?

A: Official labeling advises caution, noting that use during pregnancy should only occur if the potential benefit to the mother is judged to justify the potential risk to the fetus. The use of this medication during pregnancy requires careful consideration.

---

Q: Is it safe to breastfeed while taking Masdil Retard?

A: Diltiazem, the active ingredient, is known to be excreted in breast milk. Regulatory sources advise caution, noting that the use of this medicine during lactation should only be considered if the potential benefit is judged to justify the potential risk to the nursing child.

---

Q: Why do doctors prescribe Masdil Retard instead of other similar drugs?

A: Masdil Retard is a non-dihydropyridine Calcium Channel Blocker, which gives it a dual mechanism of action. Official information highlights its ability to affect both the peripheral blood vessels (promoting vasodilation) and the heart's electrical conduction system (controlling rate and rhythm). This comprehensive action may be preferred for certain cardiovascular needs.

---

Q: Can Masdil Retard be split in half?

A: No, the prolonged-release tablet cannot be split. The integrity of the extended-release feature requires the entire tablet to be swallowed intact. Splitting the tablet would disrupt the controlled-release feature that ensures the drug is delivered consistently over 24 hours.

---

Q: Does Masdil Retard interact with grapefruit juice?

A: Yes, official prescribing information advises that the combination of this medicine and grapefruit juice should be avoided. Grapefruit juice can potentially alter the drug’s concentration in the body.

---

Q: Can Masdil Retard cause swelling in the ankles or feet?

A: Yes, swelling in the ankles or feet, known as Peripheral Oedema, is an officially listed adverse reaction. Regulatory data classifies this as a common side effect that may affect up to 1 in 10 people.

---

Q: Can Masdil Retard interact with aspirin?

A: There is no specific official contraindication or major interaction warning listed in regulatory documents for the use of Diltiazem with aspirin. This combination should be discussed with a healthcare professional.

---

Q: Is there a generic version of Masdil Retard available?

A: Masdil Retard is a brand name for the drug containing Diltiazem hydrochloride. Generic versions of diltiazem extended-release formulations are widely available, but the availability of a specific generic product depends on local pharmacy access and regulatory approvals.

---

Q: Can Masdil Retard affect a person's sleep?

A: Insomnia (difficulty falling or staying asleep) is an officially listed adverse reaction for this medicine. Regulatory documents classify this as an uncommon effect, meaning it may affect up to 1 in 100 people.

---

Q: How should Masdil Retard tablets be stored?

A: Masdil Retard must be stored at controlled room temperature, typically below 30^circ textC. The tablets should be kept in their original container, tightly closed, and protected from both moisture and light. It must be stored out of the sight and reach of children.

---

Q: What happens if you suddenly stop taking Masdil Retard?

A: Official warnings state that treatment should not be withdrawn abruptly, but gradually reduced over time. Abrupt cessation may carry a specific risk, especially for patients with angina pectoris.

---

Q: Does Masdil Retard interact with any common over-the-counter cold medicines?

A: Many over-the-counter cold medicines contain agents that can affect heart rate or blood pressure. Regulatory documents caution against combining Diltiazem with other products that influence cardiac function, requiring careful review of ingredients in cold medicines.

---

Q: Does Masdil Retard affect sexual function?

A: Official information for the Calcium Channel Blocker drug class, to which Masdil Retard belongs, notes that reports of sexual dysfunction have been associated with this group of medicines in some patients.

---

Q: Is it normal to get headaches after starting Masdil Retard?

A: Headache is an officially listed adverse reaction and is categorized as a common effect, meaning it may affect up to 1 in 10 people. Headaches are often reported when a patient first begins therapy.

---

Q: Can I drive or operate machinery while taking Masdil Retard?

A: This medicine can cause side effects such as dizziness or low blood pressure. Official information advises patients to be aware of these potential effects before driving or operating machinery.

---

Q: What is the shelf life of Masdil Retard?

A: The official shelf life is typically listed as three years from the date of manufacture. To ensure the medication remains effective for this duration, it must be stored according to the official requirements for temperature, light, and moisture.

---

Q: Does taking Masdil Retard affect the results of any common lab tests?

A: Yes, an uncommon side effect of this medicine is an increase in liver enzyme levels, which can be detected through routine blood tests. This change is typically reversible once the drug is discontinued.

Storage Requirements

Masdil Retard (Diltiazem hydrochloride prolonged-release tablets) must be stored according to official regulatory specifications to maintain the integrity of the medication.

• Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept below 30 C and should not be frozen.
• Protection: The medicine must be kept in its original container, which should be tightly closed, and protected from moisture and light.
• Child Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Masdil Retard must follow strict regulatory guidelines.

• Restriction: Do not dispose of the tablets via wastewater, the sink, or general household refuse.
• Procedure: Unused or expired medication must be discarded according to local requirements, often through an authorized pharmaceutical take-back scheme or collection point.